

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

BT-474

RRID:CVCL_0179

Type: Cell Line

Proper Citation

RRID:CVCL_0179

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0179

Proper Citation: RRID:CVCL_0179

Description: Cell line BT-474 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Invasive breast carcinoma of no special type

Defining Citation: [PMID:94035](#), [PMID:212572](#), [PMID:1961733](#), [PMID:6582512](#), [PMID:7842014](#), [PMID:9671407](#), [PMID:10862037](#), [PMID:10969801](#), [PMID:11343771](#), [PMID:11687795](#), [PMID:12353263](#), [PMID:12800145](#), [PMID:16142302](#), [PMID:16195238](#), [PMID:16397213](#), [PMID:16417655](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:17334996](#), [PMID:18386134](#), [PMID:18516279](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:19671800](#), [PMID:19727395](#), [PMID:20070913](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21247443](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:23671654](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:24389870](#), [PMID:24456987](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26218769](#), [PMID:26589293](#), [PMID:26865974](#), [PMID:27362937](#), [PMID:27378269](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:28889351](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32942617](#), [PMID:35839778](#)

Comments: Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: ERK genetic alteration cell panel (ATCC TCP-1033)., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AKT genetic alteration cell panel (ATCC TCP-1029).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: BT-474

Synonyms: Bt-474, BT474

Cross References: BTO:BTO_0001932, CLO:CLO_0002042, EFO:EFO_0001093, MCCL:MCC:0000070, CLDB:cl497, CLDB:cl498, CLDB:cl4997, AddexBio:C0006012/4902, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:CRL-7913, ATCC:HTB-20, BCRC:60359, BCRJ:0353, BioSample:SAMN01821539, BioSample:SAMN01821618, BioSample:SAMN03473029, BioSample:SAMN10988308, BioSamples:SAMEA3516847, BioSamples:SAMEA3516848, BioSamples:SAMEA3516849, cancercellines:CVCL_0179, CCRID:1101HUM-PUMC000129, CCRID:1102HUM-NIFDC00023, CCRID:3101HUMTCHU143, CCRID:4201HUM-CCTCC00636, Cell_Model_Passport:SIDM00963, ChEMBL-Cells:ChEMBL3307636, ChEMBL-Targets:ChEMBL614529, CLS:300131, Cosmic:687464, Cosmic:871138, Cosmic:904351, Cosmic:923058, Cosmic:934520, Cosmic:946359, Cosmic:970088, Cosmic:979721, Cosmic:1000122, Cosmic:1017168, Cosmic:1018460, Cosmic:1046934, Cosmic:1047699, Cosmic:1071903, Cosmic:1129654, Cosmic:1136353, Cosmic:1176605, Cosmic:1287890, Cosmic:1289383, Cosmic:1308996, Cosmic:1434947, Cosmic:1523771, Cosmic:1603191, Cosmic:1609475, Cosmic:1945863, Cosmic:2165003, Cosmic:2301523, Cosmic:2318376, Cosmic:2361356, Cosmic-CLP:946359, DepMap:ACH-000927, DSMZ:ACC-64, DSMZCellDive:ACC-64, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:946359, GEO:GSM1716, GEO:GSM1725, GEO:GSM69198, GEO:GSM73557, GEO:GSM73702, GEO:GSM115110, GEO:GSM147888, GEO:GSM147957, GEO:GSM149981, GEO:GSM149989, GEO:GSM149997, GEO:GSM155210, GEO:GSM184392, GEO:GSM184393, GEO:GSM213707, GEO:GSM213717, GEO:GSM213718, GEO:GSM213719, GEO:GSM213737, GEO:GSM213740, GEO:GSM213743, GEO:GSM213745, GEO:GSM217615, GEO:GSM274657, GEO:GSM276780, GEO:GSM320173, GEO:GSM344341, GEO:GSM344391, GEO:GSM350504, GEO:GSM388211, GEO:GSM421861, GEO:GSM533397, GEO:GSM533412, GEO:GSM590105, GEO:GSM679677, GEO:GSM679678, GEO:GSM679679, GEO:GSM679680, GEO:GSM679681, GEO:GSM679682, GEO:GSM679683, GEO:GSM679684, GEO:GSM679685, GEO:GSM679686, GEO:GSM679687, GEO:GSM679688, GEO:GSM679689, GEO:GSM679690, GEO:GSM679691, GEO:GSM783958, GEO:GSM799168, GEO:GSM799169, GEO:GSM799170, GEO:GSM799171, GEO:GSM799172, GEO:GSM799173, GEO:GSM843476, GEO:GSM847198, GEO:GSM847453, GEO:GSM886892, GEO:GSM887957, GEO:GSM903063, GEO:GSM903064, GEO:GSM903065, GEO:GSM903066, GEO:GSM903067, GEO:GSM903068, GEO:GSM903069, GEO:GSM967821, GEO:GSM1008891, GEO:GSM1053692, GEO:GSM1172853, GEO:GSM1172941, GEO:GSM1214587, GEO:GSM1238128, GEO:GSM1264068, GEO:GSM1264073, GEO:GSM1264110, GEO:GSM1264115, GEO:GSM1374408, GEO:GSM1374409, GEO:GSM1374410, GEO:GSM1401649, GEO:GSM1669630, GEO:GSM2176271, GEO:GSM2176272, Hysigen:TCH-C139, IARC_TP53:4, IBRC:C10140, ICLC:HTL00008, IGRhCellID:BT474, KCB:KCB 2011115YJ, KCLB:60062, LiGeA:CCLE_516, LINCS_HMS:50106, LINCS_LDP:LCL-1308, NCBI_Iran:C435,

PharmacDB:BT474_109_2019, PRIDE:PXD002281, PRIDE:PXD002635, PRIDE:PXD004357, PRIDE:PXD005390, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_0179, PubChem_Cell_line:CVCL_0179, TOKU-E:694, Wikidata:Q54798460

ID: CVCL_0179

Record Creation Time: 20220427T215414+0000

Record Last Update: 20260829T231647+0000

Ratings and Alerts

No rating or validation information has been found for BT-474.

Warning: Discontinued: ATCC; CRL-7913

Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: ERK genetic alteration cell panel (ATCC TCP-1033)., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AKT genetic alteration cell panel (ATCC TCP-1029).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2878 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Mathieu C, et al. (2026) Inhibition of TRAP1 in the C-terminal domain influences mitochondria properties and breast cancer cell metabolism. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 196, 119060.

Lin X, et al. (2026) 99mTc-HP-Ark2 SPECT/CT imaging reveals dynamic HER2 regulation in trastuzumab resistance and its reversal by PI3K inhibition. International journal of cancer, 158(6), 1726.

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer research, 86(6), 1467.

??cka M, et al. (2026) Engineering Cathepsin S Selective Chemical Probes and Antibody-Drug Conjugates through Substrate Profiling with Unnatural Amino Acids. Journal of

medicinal chemistry, 69(14), 16550.

Gao A, et al. (2026) Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer. *Cancer research*, 86(13), 3287.

Luque M, et al. (2026) Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer. *Neoplasia (New York, N.Y.)*, 78, 101318.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. *Cell reports. Medicine*, 7(7), 102922.

Wang K, et al. (2026) Peptide-centric local stability assay (PELSA) for sensitive identification of ligand-targeting proteins and binding sites at proteome scale. *Nature protocols*.

Cao Y, et al. (2026) Sequential cryoablation enhances chemotherapeutic efficacy in pancreatic cancer by downregulating TGF- β mediated fibrosis in the sub-lethal zone. *Journal of thermal biology*, 139, 104503.

Cruz A, et al. (2026) Targeting TNBC: core-shell polycationic polyurea dendrimers with inherent anticancer activity. *FEBS open bio*, 16(5), 944.

Nandi D, et al. (2026) Spermine Oxidase Serves as a Key Functional Node in Microbial Dysbiosis-Induced Breast Carcinogenesis. *Cancer research*, 86(8), 1920.

Takeda S, et al. (2026) A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. *Cancer research*, 86(8), 2024.

Matsuura K, et al. (2026) Distinct metabolic dependency on BCAA defines cancer stemness and malignancy in human triple-negative breast cancer. *Cell reports*, 45(7), 117630.

Wang ZW, et al. (2026) Combinatorial inhibition of IGF2BP3-regulated receptor tyrosine kinases offers a new therapeutic strategy for triple-negative breast cancer. *Journal of experimental & clinical cancer research : CR*, 45(1).

Guo Y, et al. (2026) miR-3648 regulates cell functions and acts as a potential biomarker to predict prognosis in breast cancer and its bioinformatics analysis. *World journal of surgical oncology*, 24(1).

Yue Z, et al. (2026) Subcellular Redistribution of Endomembrane GPR15 Promotes NAD⁺-Mediated Metabolic Reprogramming and Boosts 5-FU Chemosensitivity in Colorectal Cancer. *Cancer research*, 86(9), 2253.

Hou L, et al. (2026) C-type lectin domain family 5 member A-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy. *Journal for immunotherapy of cancer*, 14(4).

Wang B, et al. (2026) Label-free interferometry platform for drug response profiling of bioprinted tumor organoids at single-organoid resolution. *Nature protocols*.

Zhang W, et al. (2026) Single-Cell and Multiomics Characterization of p21 in Cancer Progression and Therapeutic Sensitivity. *Human mutation*, 2026, 5598948.

Lin W, et al. (2026) FAM135B Deficiency Inhibits Cytotoxic T-cell Activity in Triple-Negative Breast Cancer by Blocking the IFI16-Dependent STING Pathway. *Cancer immunology research*, 14(2), 335.